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Clinical Pharmacology of Tisagenlecleucel in
B-cell Acute Lymphoblastic Leukemia
Karen Thudium Mueller1, Edward Waldron2, Stephan A. Grupp3,4,
John E. Levine5,6, Theodore W. Laetsch7,8, Michael A. Pulsipher9,
Michael W. Boyer10, Keith J. August11, Jason Hamilton12, Rakesh Awasthi1,
Andrew M. Stein13, Denise Sickert14, Abhijit Chakraborty2, Bruce L. Levine15,
Carl H. June15, Lori Tomassian2, Sweta S. Shah2, Mimi Leung2, Tetiana Taran2,
Patricia A. Wood2, and Shannon L. Maude3,4

Abstract
Purpose: Tisagenlecleucel is an anti-CD19 chimeric antigen
receptor (CAR19) T-cell therapy approved for the treatment of
children and young adults with relapsed/refractory (r/r) B-cell
acute lymphoblastic leukemia (B-ALL).
Patients and Methods: We evaluated the cellular kinetics
of tisagenlecleucel, the effect of patient factors, humoral
immunogenicity, and manufacturing attributes on its kinetics, and exposure-response analysis for efﬁcacy, safety and
pharmacodynamic endpoints in 79 patients across two
studies in pediatric B-ALL (ELIANA and ENSIGN).
Results: Using quantitative polymerase chain reaction to
quantify levels of tisagenlecleucel transgene, responders
(N ¼ 62) had 2-fold higher tisagenlecleucel expansion
in peripheral blood than nonresponders (N ¼ 8; 74% and
104% higher geometric mean Cmax and AUC0-28d, respectively) with persistence measurable beyond 2 years in
responding patients. Cmax increased with occurrence and
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severity of cytokine release syndrome (CRS). Tisagenlecleucel
continued to expand and persist following tocilizumab,
used to manage CRS. Patients with B-cell recovery within
6 months had earlier loss of the transgene compared with
patients with sustained clinical response. Clinical responses
were seen across the entire dose range evaluated (patients
50 kg: 0.2 to 5.0  106/kg; patients >50 kg: 0.1 to 2.5 
108 CAR-positive viable T cells) with no relationship
between dose and safety. Neither preexisting nor treatment-induced antimurine CAR19 antibodies affected the
persistence or clinical response.
Conclusions: Response to tisagenlecleucel was associated with increased expansion across a wide dose range.
These results highlight the importance of cellular kinetics
in understanding determinants of response to chimeric
antigen receptor T-cell therapy. Clin Cancer Res; 24(24); 6175–84.
2018 AACR.

Introduction
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Chimeric antigen receptor (CAR) T-cell therapy is an autologous, adoptive cellular treatment strategy that uses genetic
engineering to graft speciﬁcity into an immune effector cell
(1). Unlike other small-molecule or antibody therapies, whose
levels decrease over time, CAR-T cells are "living drugs" that
undergo rapid exponential expansion and can persist for
months or even years. Characterization of the cellular kinetics
of CAR-T cells and factors impacting kinetics is of great importance for understanding the efﬁcacy, safety, and recommended
dose range.
Tisagenlecleucel (formerly CTL019) is a CAR-T-cell immunotherapy using patient-derived T cells that have been genetically engineered ex vivo via lentiviral transduction to express a
CD19-targeted CAR (CAR19) that mediates T-cell activation in
a major histocompatibility complex–independent manner.
CAR19 is composed of a murine single-chain Fv antibody
fragment that recognizes CD19 and is fused to a costimulatory
domain from 4-1BB (CD137) and an intracellular signaling
domain, CD3z (2). The CD3z component is critical for initiating T-cell activation and antitumor activity, while 4-1BB
enhances the expansion and persistence of tisagenlecleucel
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Translational Relevance
CD19-directed chimeric antigen receptor T-cell therapies
(CAR-T) offer patients with hematologic cancers new treatment options. However, an in-depth characterization of
CAR-T cellular kinetics, dose, and immunogenicity is lacking and yet is essential to understanding the safety and
effectiveness of these therapies. Here, we present the ﬁrst
comprehensive analysis characterizing cellular kinetics and
clinical pharmacology aspects of tisagenlecleucel, a CAR-T,
to support the recommended dose range, safety, and efﬁcacy
proﬁle in a pooled study of pediatric and young adult
patients with relapsed/refractory B-cell acute lymphoblastic
leukemia. This work highlights the relationship between
tisagenlecleucel persistence and on-target effects and
demonstrates continued expansion and persistence following tocilizumab administration for cytokine release syndrome. Furthermore, we show that immunogenicity does
not affect the safety or efﬁcacy of tisagenlecleucel. This work
advances the understanding of the clinical pharmacology
aspects of CAR-T and the methodologies discussed may
translate to new indications or other CAR-T targets.

(2, 3). Upon binding to CD19-expressing cells, the CAR transmits a signal to promote T-cell activation, expansion, target-cell
elimination, and persistence of the tisagenlecleucel cells (2).
Tisagenlecleucel represents an effective treatment modality in
patients with speciﬁc B-cell malignancies for whom other
therapies have failed (4, 5).
The unique pharmacology of CAR-T cells was reported with the
initial characterization of the cellular kinetics of tisagenlecleucel
in single-center studies in pediatric and adult patients with
relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia
(B-ALL) and patients with chronic lymphocytic leukemia (CLL;
ref. 6). The results from these prior studies demonstrate higher
expansion of tisagenlecleucel cells in the responding patients
compared with nonresponding patients across these multiple
indications. Furthermore, an association between expansion,
tumor burden, and cytokine release syndrome (CRS) was
reported, whereby high grades of CRS were observed in patients
with higher baseline tumor burden and higher expansion (6). The
importance of long-term persistence of circulating tisagenlecleucel cells in producing durable responses in patients with CLL or
ALL has been previously presented.
The current report extends the characterization of cellular
kinetics to tisagenlecleucel with the ﬁrst comprehensive analysis detailing the relationship of patient characteristics and
clinical outcomes, including efﬁcacy and safety, in regard to
tisagenlecleucel dose, immunogenicity, B-cell recovery, and the
impact of tocilizumab on the cellular kinetics in pediatric and
young adult patients ages  25 years with r/r B-ALL treated on
two multicenter trials.

Patients and Methods
Clinical trial design and patients
Data collected from patients enrolled in the studies ELIANA
(ref. 5; N ¼ 50) and ENSIGN (ref. 7; N ¼ 29) were pooled for
this analysis as these multicenter studies enrolled identical
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patient populations and had similar study designs. Pooling
the data allowed for a more robust analysis with an appropriate
number of patients to evaluate clinical pharmacology endpoints. The global, multicenter ELIANA study was sponsored
and designed by Novartis Pharmaceuticals Corporation and
supported by Novartis manufacturing process. The US multicenter ENSIGN trial was codeveloped by Novartis and the
University of Pennsylvania and was supported by the University of Pennsylvania manufacturing processes (5, 7). Comparability studies were performed between manufacturing sites
as part of the technology transfer from the University of
Pennsylvania to Novartis. The pivotal, single-arm, open-label,
phase II ELIANA study was conducted at 25 sites and aims to
determine the efﬁcacy and safety of tisagenlecleucel in pediatric
and young adult patients with r/r B-ALL ages between 3 years at
the time of screening and 21 years at the time of initial
diagnosis (5). The patients from the phase II ENSIGN study
were treated at nine sites (7). For both studies, patients were
required to have active bone marrow disease (5% blasts) at
enrollment and no prior anti-CD19 therapy (5, 7). The protocol-speciﬁed dose ranges studied were 0.2 to 5.0  106 CAR19positive viable T cells per kg body weight in patients who
weighed  50 kg and 0.1 to 2.5  108 CAR19-positive viable
T cells in patients who weighed > 50 kg, administered as a single
infusion of 10 to 20 mL per minute.
Characterization of the clinical pharmacology includes summary statistics of the cellular kinetics by clinical response
category; justiﬁcation of the proposed dose range with doseresponse, exposure-response, and dose-exposure analysis; evaluation of the impact of intrinsic and extrinsic factors on
expansion; dose-safety analysis; and the evaluation of the
impact of humoral immunogenicity on the cellular kinetics
and effectiveness of tisagenlecleucel. Furthermore, the relationship between selected manufacturing characteristics and expansion has been evaluated. Additional insights on this unique
living drug are presented here to enhance the understanding
of the clinical relevance of the exposure data in terms of both
efﬁcacy and safety.
Bioanalytical methods
Cellular kinetic assays. A TaqMan-based qPCR assay was used for
the detection of tisagenlecleucel transgene DNA (transgene copies/mg of DNA) in peripheral blood and bone marrow samples,
with a lower limit of quantitation of 50 copies/mg of genomic
DNA requiring 200 ng DNA/reaction. The assay tolerates 10%
variation in DNA input. This method was originally developed
by the University of Pennsylvania and later validated by Navigate
BioPharma Services for sample analysis. A 9-marker, 8-color ﬂow
cytometry assay was developed by Navigate BioPharma Services
to detect and quantify tisagenlecleucel-positive CD3-positive
T cells. Humoral immunogenicity was detected using a validated
ﬂow cytometry assay measuring mCAR19 antibodies in specimens collected before and after tisagenlecleucel infusion.
Anti-mCAR19 IgM/IgG antibodies in human serum specimens
were captured by Jurkat cells (an immortalized line of human
T lymphocyte cells) transfected to express mCAR19. This method
has a sensitivity of 100 ng/mL of positive control antibody in
100% human serum.
Cellular kinetics. The cellular kinetics of tisagenlecleucel were
determined by measurement of transgene by both qPCR and the
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presence of CAR19 protein expressed on the surface of CARpositive T cells (CD3þ, CARþ) as measured by ﬂow cytometry.
The cellular kinetic parameters (AUC0-28d, Cmax, Tmax, Tlast,
T1/2) were derived from peripheral blood samples, and parameters were estimated by noncompartmental methods using
Phoenix (Pharsight, Version 6.4). The area under the curve
(AUC0-28d) of tisagenlecleucel represents the expansion and
persistence of tisagenlecleucel during the ﬁrst 28 days following infusion. Cmax corresponded to the maximum (peak)
expansion of tisagenlecleucel, while Tmax corresponded to the
time at which this maximum expansion was observed. Conventional methods were used to derive additional cellular
kinetic parameters, such as the last observed quantiﬁable level
of transgene (Clast), Tlast, and T1/2. Summary statistics of cellular kinetic parameters from peripheral blood were summarized
by clinical response at day 28, and levels of transgene in bone
marrow were summarized by time points (e.g., day 28; months
3, 6, 9, and 12). Due to the challenges in estimating T1/2, a
population cellular kinetic model was also used to characterize
these data. It modeled tisagenlecleucel as having an exponential
growth phase at rate r, followed by a biexponential decline at
rates a and b. Further details are available in the Supplementary
Material available online with this article. The day 28 clinical
response assessment in both studies was based on the NCCN
Clinical Practice Guidelines in Oncology—Acute Lymphoblastic
Leukemia V1.2013 (8).
Patient characteristics and prior treatment on cellular kinetics
The impact of patient characteristics and prior clinical treatment factors was explored using linear models, scatter plots, box
plots, and summary statistics and pharmacometric model (Supplementary Fig. S1; ref. 9).The impact on cellular kinetics of
administration of tocilizumab and corticosteroids, which were
administered based on a protocol-deﬁned treatment algorithm
for CRS management, was also evaluated.
Dose-exposure, exposure-response, and dose-response analysis
The relationships between dose-response, exposure-response,
as well as between dose/exposure and safety events, were explored
using logistic regression models and quartile analysis. Cox regression models and Kaplan–Meier analyses were used to explore the
relationship between dose/exposure and time-to-event endpoints
such as duration of response and resolution of hematopoietic
cytopenias.
Relationship between cellular kinetics and B-cell aplasia
The relationship between cellular kinetics and B-cell aplasia
was evaluated through event-free survival (EFS) graphical analysis. As part of the pharmacodynamic characterization, peripheral
blood B cells were measured in all patients. B-cell recovery was
deﬁned as >1% B cells/WBCs or >3% B cells/lymphocytes (the
lower limit of normal for blood B-cell levels).
Humoral immunogenicity
Antimurine CAR19 (mCAR19) antibodies were measured in
serum collected before and after tisagenlecleucel infusion for the
determination of humoral immunogenicity. Humoral immunogenicity was determined by measurement of anti-mCAR19 antibodies in serum by ﬂow cytometry. Anti-mCAR19 antibodies
were captured by Jurkat T cells transduced to express murine
CAR19. To differentiate the anti-mCAR19 antibodies from those
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speciﬁc to antigens on Jurkat T cells, specimens were also tested
separately on wild-type Jurkat cells. After an incubation step,
washing away any unbound substances, an anti-IgG/IgM F(ab')
2 fragment labeled with R-Phycoerythrin was added in addition to
a viability dye (eFluor 780). After incubation, additional washing
steps, and a ﬁxating step, the samples were analyzed on a ﬂow
cytometer. The impact of anti-mCAR19 antibodies on cellular
kinetics and efﬁcacy was explored using box plots and summary
statistics.
Study approval
The ELIANA and ENSIGN studies were conducted in accordance with the principles of the Declaration of Helsinki and were
approved by the institutional review board at each participating
institution; all patients or their guardians provided written
informed consent (5, 7).

Results
Patient characteristics
Cellular kinetic data were pooled from two multicenter trials,
ELIANA (a global study, N ¼ 50) and ENSIGN (a US-based
study, N ¼ 29), in pediatric and young adult (age, 3–25 years;
median, 12.0 years) patients with r/r B-ALL following a single
infusion with tisagenlecleucel (ELIANA: NCT02435849;
ENSIGN: NCT02228096). Baseline demographics and disease
characteristics, which were previously reported (6), are summarized in Supplementary Table S1.
Cellular kinetics of tisagenlecleucel in peripheral blood
Following infusion of tisagenlecleucel, the cells distribute
throughout the body. Upon binding to the CD19 antigen,
tisagenlecleucel cells proliferate and the transgene levels undergo a rapid multi-log expansion beyond the initial infused
dose (determined by quantitative polymerase chain reaction
[qPCR]), followed by subsequent biexponential decline. A
representation patient proﬁle reﬂective of the expansion and
persistence seen in responder patients is presented in Fig. 1.
Median maximal expansion (Cmax) and exposure during the
ﬁrst 28 days following infusion (AUC0-28d) were higher in
patients who achieved complete remission (CR) or CR with
incomplete blood count recovery (CRi) compared with nonresponding (NR) patients: 226% higher for AUC0-28d and
104% higher for Cmax (Table 1). Although no statistically
signiﬁcant difference was observed due to the small population
of NR patients (n ¼ 8), CR/CRi patients tended to have a higher
and earlier expansion compared with NR patients (Supplementary Fig. S2). Furthermore, for both the ﬂow cytometry– and
qPCR-based assessments, the Cmax and AUC0-28d trend clearly supports this analysis, showing limited to no expansion in
NR patients compared with high expansion and persistence
in CR/CRi patients. These ﬁndings are consistent with previous reports describing the difference in expansion between
responding and NR patients (6). In the ELIANA study, the
surface expression of CAR19 (% CD3þCARþ cells) was characterized by ﬂow cytometry (Supplementary Fig. S3). Expansion and persistence of CD3þCARþ cells were detected by
ﬂow cytometry in all patients. Flow cytometry–based measurements were used to quantify levels of CAR-expressing T cells
as this method is able to measure the surface expression of
the CD19 CAR in contrast to the qPCR assay that measures
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the bulk transgene level. Median peak expansion in responding patients was 31.6% CD3þCARþ cells (range, 1.10–84.9)
with persistence detected up to 9 months; with additional
follow-up, the persistence of CD3þCARþ cells is anticipated
to lengthen. Importantly, in the ELIANA study, limited expansion with rapid clearance of surface CARþ cells was detected in
NR patients as determined by ﬂow cytometry (0%, 0%, and
17.3%); only one of these NR patients achieved B-cell aplasia
and all NR patients had measurable bone marrow blasts at
day 28. Persistence was observed at low levels up to month
3 (12.1%) in a single NR patient with CD19-negative disease.
The median number of days to reach maximum expansion
(Tmax) determined by qPCR was achieved at day 10 in
responding patients with a delayed Tmax of 20 days in NR
patients (Fig. 2; Table 1).
We previously reported a signiﬁcant difference in expansion
between patients in CR/CRi and NR as detected by ﬂow cytometry
(6). In the present data, the maximum expansion determined
from ﬂow cytometry revealed a geometric mean maximum level
of surface expression of 21.4 % (CV%, 145.2) in responding
patients, although measurable in only one NR patient at a
maximum expansion level of 17.3% with rapid clearance that
was no longer detected by ﬂow cytometry. Determination of
AUC0-28d by ﬂow cytometry requires at least three samples with
detectable levels, which no NR patient achieved; therefore, this
parameter could not be assessed in nonresponding patients. The
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Figure 1.
Tisagenlecleucel cellular kinetics.
Tisagenlecleucel cellular kinetics
from a representative proﬁle of a
patient with pediatric B-ALL in the
ELIANA study showing the initial
expansion phase to day 28 (A) and
day 300 (B). LLOQ, lower limit of
quantitation.

300

lack of expansion seen in NR patients represents the importance
of performing ﬂow cytometry analyses in clinical development
for conﬁrmation of functional CARs in vivo. In NR patients, CAR-T
cells took longer to engraft and expand, a phenomenon observed
in other trials as well (6). A trend toward a longer T1/2 was noted
in patients with CR/CRi (16.8 days) compared with NR patients
(2.5 days); however, the T1/2 estimates in NR patients were
limited by low numbers and short follow-up of NR patients.
Persistence of transgene (Tlast) was detectable up to 380 days,
with a median of 102 days (range, 17.8–380 days) in patients with
CR/CRi, and 27.8 days (range, 20.9–83.9 days) in NR patients
(Fig. 2). Notably, both parameters, Tlast and apparent T1/2, were
dependent on the data cutoff date and length of assessment.
A summary of these values is reported in Table 1. Due to the
challenges of limited data in estimating individual-level T1/2
values using noncompartmental analysis, a pharmacometric
approach was implemented. A nonlinear mixed-effect population cellular kinetic model was also used to characterize the
exponential growth and biexponential decline by qPCR. The
initial T1/2 of decline (after Tmax) was estimated to be 4.3 days
(coefﬁcient of variation [CV], 91%), and the terminal T1/2 was
estimated to be 220 days (CV 86%) in responding patients.
Tisagenlecleucel dose and cellular kinetics
Dose-exposure analysis showed a ﬂat relationship between
dose and the cellular kinetic parameters, with r2 < 0.001

Table 1. Tisagenlecleucel cellular kinetic parameters in responding patients and nonresponding patients
Parameter
Statistic
CR/CRi (N ¼ 62)
AUC0-28d, copies/mg of DNA  days
n
61
Geometric mean (CV%)
318,000 (177.8)
Percent change (CR/CRi vs. NR)
104%
Median (range)
420,000 (21,000–2,740,000)
a
n
61
Cmax, copies/mg
Geometric mean (CV%)
34,700 (155.4)
Percent change (CR/CRi vs. NR)
74%
Median (range)
44,800 (2,210–316,000)
Tmax, days
n
61
Median (min–max)
9.91 (0.00764–27.0)
T1/2, days
n
54
Geometric mean (CV%)
16.8 (155.9)
Tlast, days
n
62
Median (min–max)
102 (17.8–380)

NR (N ¼ 8)
6
156,000 (99.4)
129,000 (72,300–711,000)
7
20,000 (71.6)
22,000 (9,700–57,700)
7
20.0 (0.0278–62.7)
3
2.52 (171.9)
8
27.8 (20.9–83.9)

Abbreviations: AUC, area under the curve; Cmax, maximum (peak) expansion; CR, complete remission; CRi, complete remission with incomplete blood count
recovery; CV%, coefﬁcient of variation; max, maximum; min, minimum; NR, nonresponding response; T1/2, half-life; Tlast, time of last measurable in peripheral
blood; Tmax, time to reach maximum (peak) peripheral blood tisagenlecleucel transgene level.
a
Seven patients had a Cmax determined from samples collected <1 day after infusion; these samples may represent the amount of tisagenlecleucel in the catheter
rather than the amount of expanded tisagenlecleucel.
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Figure 2.
Cellular kinetics of tisagenlecleucel
transgene by response in the ELIANA
study.

and ¼ 0.002 for Cmax and AUC0-28d, respectively (Supplementary Table S2; Supplementary Fig. S4). Thus, there was no
relationship between AUC0-28d or Cmax and total weightadjusted tisagenlecleucel cell dose or total CAR-positive viable
T-cell dose across a wide dose range of 0.2 to 5.0  106 CAR19positive viable T cells per kg of body weight in patients
weighing 50 kg and 0.1 to 2.5  108 CAR19-positive viable
T cells in patients weighing > 50 kg. In responding patients, high
trafﬁcking and penetration of tisagenlecleucel in bone marrow
was detected with a proﬁle consistent with that seen in peripheral blood. CAR19 transgene partitioning of blood to bone
marrow ranged from 28% to 71% over 6 months. The blood to
bone marrow partitioning suggests that transgene distribution
in bone marrow was 44% of that present in blood at day 28
while at months 3 and 6, it distributed at 67% and 68.8%.
Impact of demographic, disease-speciﬁc characteristics, and
prior therapies on cellular kinetics
Baseline tumor burden, cytogenetics, disease characteristics,
patient demographics [age (Supplementary Fig. S5A), race,
body weight, gender (Supplementary Fig. S5B)], and disease
status did not affect cellular kinetic parameters (AUC0-28d and
Cmax). We previously reported that patients with higher tumor
burden have greater expansion (4–6); however, a similar analysis was not performed for the pooled data set because tumor
burden was not assessed immediately prior to tisagenlecleucel
infusion as it was in the single-center trial (NCT01626495).
We also assessed whether prior therapies (e.g., number
of lines or prior stem cell transplant) affected cellular kinetics.
Prior stem cell transplant (Supplementary Fig. S5C), the number of lines of prior therapies (Supplementary Fig. S5D), and
the type of lymphodepletion regimen used did not affect
expansion and persistence of the transgene. It should be noted,
however, that the majority of patients received ﬂudarabinebased lymphodepletion chemotherapy.
Tisagenlecleucel dosing and efﬁcacy
Efﬁcacy was observed across the entire dose range studied. A
quartile analysis revealed consistent response rates across all dose

www.aacrjournals.org

quartiles (Supplementary Table S3), and similar response rates
were seen at the lowest and highest dose quartiles. Logistic
regression analyses showed an increasing probability of response
with dose, where a doubling in weight-adjusted dose was associated with a 97% increase in odds of response [odds ratio, 1.97
(95% CI, 1.183–3.293)]; however, the numbers of patients,
especially those treated at low doses, were small (at dose < 1 
106 CAR19-positive viable T cells/kg), and the 95% CIs were wide
(response rate, 5%–95%; Supplementary Fig. S6A). Similarly, for
patients who weighed >50 kg, the dose-response showed
decreased probability of response with doses <2.0  106
CAR19-positive viable T cells/kg, and the probability of response
plateaued with higher doses. The highest feasible dose is always
attempted; however, due to individual apheresis and patient
characteristics, infused doses may be on the lower end of the
dose range. A logistic regression dose-response analysis was
performed for the single-dose administration of tisagenlecleucel.
A doubling in total dose was associated with a 78% increase in
odds of response with a wide conﬁdence interval due to limited
data at the lower end of the dose range [odds ratio, 1.78 (95% CI,
1.098–2.883); Supplementary Fig. S6B]. The model-predicted
probability of response for patients treated with the lowest
administered dose for both weight categories was 43% and
30.9% for patients 50 kg and >50 kg, respectively. It should be
noted that the studies were not designed to detect a dose–response
relationship, and the exact dose given to an individual patient was
not predeﬁned but rather based on patient-speciﬁc characteristics
and manufacturing feasibility.
Tisagenlecleucel dosing and safety
The most common adverse events (AEs) in ELIANA and
ENSIGN were CRS, neurologic events, and cytopenias; therefore, the relationship between these AEs of interest and dose
was evaluated. CRS occurred in 82.4% of patients. Logistic
regression analysis of the relationship between tisagenlecleucel
dose and CRS grade indicated that there was no impact of
CAR-positive viable T-cell dose on the probability of grade 3
or 4 CRS (Supplementary Fig. S7). Transient neurologic events
were reported in 37 patients (40.7%) within 8 weeks of
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tisagenlecleucel infusion (10). Cytopenias not resolved by
day 28 were reported in 35.2% of patients. Neither neurologic
events nor cytopenias not resolved by day 28 were found to be
affected by the CAR-positive viable T-cell dose (Supplementary
Figures S8 and S9).
Tisagenlecleucel CD4:CD8 ratio in ﬁnal product
The importance of the CD4:CD8 ratio is a relevant question
within the ﬁeld of CAR-T therapies. The CD4:CD8 ratio in the
ﬁnal product was determined for the ELIANA study, and the
relationship between clinical response, safety, and in vivo
expansion was evaluated (Supplementary Fig. S10A–S10F). The
results of these analyses demonstrate a similar CD4:CD8 ratio
between CR/CRi and NR patients based on clinical response
assessments performed at day 28 (Supplementary Fig. S10A–
S10B) with no differences in the CD4:CD8 ratio based on
highest grade of CRS (Supplementary Fig. S10C–S10D). Finally, in vivo expansion (Cmax) is independent from the CD4:CD8
ratio (Supplementary Fig. S10E–S10F).
Impact of CRS severity and anticytokine therapy
The administration of anticytokine agents coincided with the
peak of CRS, which was often concurrent with maximal expansion of tisagenlecleucel. Tocilizumab was administered to
42.7% of patients in accordance with the CRS treatment algorithm (11). Tisagenlecleucel continued to expand and persist
following the administration of tocilizumab (Fig. 3). The tisagenlecleucel AUC0-28d and Cmax were 265% and 183% higher
in responding patients treated with tocilizumab than in patients
not treated with tocilizumab. The higher expansion observed
in patients who received tocilizumab cannot be directly attributed to tocilizumab administration as it was used to treat
those with higher-grade CRS, who showed higher expansion
than patients with grade 1 or 2 CRS (Supplementary Fig. S11).
Additionally, corticosteroids, in limited doses and duration,
together with or after inadequate response to tocilizumab, were
administered to 25.3% of patients for the management of CRS.
AUC0-28d and Cmax were 89% and 55% higher, respectively, in
responding patients treated with corticosteroids [geometric
mean AUC0-28d, 509,000 (range, 39,300–2,100,000); geometric CV%, 196.8%; geometric mean Cmax, 47,800 (range, 4,040–
146,000); geometric CV%, 140.9%] than those not treated with
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Manufacturing attributes and cellular kinetics
The relationship between selected tisagenlecleucel product
attributes, including cell viability, transduction efﬁciency, total
T-cell number, and cellular kinetic parameters, was evaluated.
There was no relationship between these select manufacturing
attributes and the log-transformed cellular kinetic parameters
(AUC0-28d, Cmax, and Tmax) determined by qPCR (Supplementary Table S5; Supplementary Figs. S13 and S14), within the
observed data range.
B-cell pharmacodynamics
B-cell count in the peripheral blood is a pharmacodynamic
marker for functional persistence of tisagenlecleucel cells as
B-cell aplasia is an on-target effect of tisagenlecleucel. The
relation between time to B-cell recovery and tisagenlecleucel
persistence was determined. This analysis shows that patients
with B-cell recovery occurring before 3 months or between
3 and 6 months had more rapid loss of transgene than patients who had sustained B-cell aplasia beyond 6 months
(Fig. 4). Furthermore, a Kaplan–Meier analyses for time to
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Cellular kinetics and event-free survival
The cellular kinetics of tisagenlecleucel transgene were correlated with EFS. Patients with events prior to 6 months had rapid
loss of CAR compared with patients with EFS  6 months
(Supplementary Fig. S12). Separation of the curves was most
pronounced at approximately month 6 (day 183); however, the
number of patients with EFS < 6 months was low (n ¼ 7), and
hence, there was no statistically signiﬁcant difference.
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corticosteroids [geometric mean AUC0-28d, 269,000 (range,
21,000–2,740,000); geometric CV%, 162.9%; geometric mean
Cmax, 30,900 (range, 2,210–316,000); geometric CV%,
158.0%]. Although there was no relationship between tisagenlecleucel dose and CRS grade, or between dose and expansion as
described above, patients with higher-grade CRS tended to have
greater tisagenlecleucel expansion (Supplementary Fig. S11 and
Supplementary Table S4); a doubling in Cmax was associated
with a 59% increase in the odds of experiencing grade 3 or 4 CRS
(odds ratio, 1.59; 95% CI, 1.091–2.302). There were an insufﬁcient number of NR patients treated with tocilizumab and
steroids to perform similar analyses.

100,000

Tocilizumab doses
1 dose
>1 dose
No tocilizumab

10,000

1,000

100

Figure 3.
The impact of tocilizumab on
tisagenlecleucel expansion and
persistence. Days 0 to 28 (A) and days
0 to 600 (B) after tisagenlecleucel
infusion. Persistence of
tisagenlecleucel was observed for up
to 457 days. Data presented are for an
updated data cut with 68 patients who
received tisagenlecleucel infusion.
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18 study visit.
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Figure 4.
Tisagenlecleucel transgene levels by B-cell recovery time.

B-cell recovery shows the median time to recovery is around
11.4 months (Supplementary Fig. S15).
Cellular kinetics and MRD assessment
CD19-positive relapses were associated with lower expansion and more rapid loss of transgene than that seen in patients
with sustained response (Fig. 5). Patients with a CD19-negative
relapse had transgene levels comparable with those seen in
patients with sustained responses with approximately 200 days
of follow-up (Fig. 5).
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Figure 5.
Cellular kinetics of tisagenlecleucel by
relapse category and sustained
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Humoral immunogenicity
Before infusion, speciﬁc antimurine CAR19 (mCAR19) antibodies were detected in 84.8% of patients treated with tisagenlecleucel. Preexisting anti-mCAR19 antibodies and treatment-
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induced or treatment-boosted anti-mCAR19 antibodies did not
affect the expansion or cellular kinetics of tisagenlecleucel (Supplementary Fig. S16), nor did preexisting antibodies affect
response or relapse (Supplementary Fig. S17).
After infusion, induced or boosted humoral immunogenicity
was observed in 36.7% of patients treated with tisagenlecleucel.
Treatment-induced immunogenicity was determined by a
positive increase in measurable anti-mCAR19 antibodies from
the baseline sample collected from an individual patient at
enrollment and patient's speciﬁc cutoff point. No differences
were observed in the AUC0-28d values in regard to baseline antimCAR19 antibodies (Supplementary Fig. S16A). A concentration–
time proﬁle of tisagenlecleucel transgene by presence or absence
of treatment-induced immunogenicity showed consistent
exposure between the two groups (Supplementary Fig. S16B).
Furthermore, treatment-induced anti-mCAR19 antibodies did
not affect efﬁcacy, safety, or cellular kinetics of tisagenlecleucel
(12). There was no impact of preexisting or treatment-induced
immunogenicity on day 28 clinical response (Supplementary
Fig. S18). The impact of treatment-induced immunogenicity
on duration of remission was determined. The duration
of response was comparable in patients with anti-mCAR19
antibody levels above and below the median level of detected
anti-mCAR19 antibodies (Supplementary Fig. S17). Cox regression analyses show no statistically signiﬁcant impact on DOR
(Supplementary Table S6).

Discussion
Characterization of the clinical pharmacology of CAR-T therapies is fundamental to understanding the clinical efﬁcacy and
safety data to support the recommended dose for these novel
therapies. In this pooled analysis of two multicenter trials of
tisagenlecleucel, the cellular kinetic analyses showed that
responding patients had higher expansion than NR patients, as
determined by qPCR, with limited expansion detected in NR
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patients by ﬂow cytometry. This ﬁnding underscores the lack of
CAR expression on the cell surface, which is required for CAR
function, in NR patients and is consistent with observations
in the original study conducted by the Children's Hospital of
Philadelphia (4, 6). Although the ﬂow cytometry–based measurements can be more discriminating in accounting for proliferation and persistence of the surface CARþ T cells, the high
sensitivity of qPCR allowed tracking of tisagenlecleucel over a
much longer period, furthering our understanding of the relationship between persistence and durability of remission with
tisagenlecleucel. B-cell levels are a pharmacodynamic surrogate
marker for functional persistence of tisagenlecleucel because
of the on-target effect of tisagenlecleucel on normal and malignant CD19-positive B cells with resultant B-cell aplasia. Measurement of CAR transgene in patients treated with tisagenlecleucel
is an important aspect for characterizing the in vivo activity
of tisagenlecleucel in clinical trials; however, outside the clinical trial setting, this study suggests B cells are an appropriate
marker to guide treatment of patients with B-ALL. The results of
these analyses demonstrated that B-cell aplasia may be a useful
surrogate to evaluate CAR persistence.
The time to B-cell recovery curve (Supplementary Fig. S15)
closely resembles the duration of remission analyses previously
reported (13). At this time, we hypothesize that a minimum of
6 months of B-cell aplasia is necessary to prevent CD19-positive
relapses (Fig. 4 and Supplementary Fig. S15), but further followup data are required.
In previous studies, we have shown that tisagenlecleucel
persistence is an important contributor to durable remission
(4). We attempted to assess the impact of cellular kinetics on
EFS; persistence of B-cell aplasia for a minimum of 6 months is
necessary to prevent CD19-positive relapse; however, due to
limited data surrounding early loss of CAR and short follow-up,
more data are needed, and longer follow-up will be required to
fully understand optimal duration of CAR-T-cell persistence.
CRS is the most common, and expected, AE observed in
pediatric and young adult B-ALL patients treated with CAR-Tcell therapies (13). Consistent with previous studies of tisagenlecleucel, patients with higher tumor burden were at increased
risk of higher-grade CRS and had greater in vivo tisagenlecleucel
expansion. Patients with severe CRS (graded on the Penn
grading scale; ref. 11) received tocilizumab and/or corticosteroids. In these analyses, we have shown that the administration
of anticytokine agents or low-dose corticosteroids did not affect
the in vivo expansion or persistence of the CAR; however, the
impact of these agents on the cellular kinetics of tisagenlecleucel
was not formally evaluated in a randomized study. These ﬁndings support the administration of tocilizumab and low-dose
corticosteroids in patients with high-grade CRS or life-threatening emergencies without impacting in vivo kinetics or response.
It is important to acknowledge that patients received low-dose
corticosteroids (2 mg/kg) for a short duration and are weaned
rapidly. Limited data exist on the impact of high doses of
steroids over a long duration on CAR-T-cell expansion and
persistence; therefore, we do not recommend this approach.
Further studies will need to be performed to determine whether
treating patients with tocilizumab prophylactically would mitigate the severity of CRS or interfere with tisagenlecleucel
expansion and function. As more CAR-T therapies become
available with varying CRS management algorithms/recommendations, it is important to fully characterize the impact of earlier
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administration of anticytokine therapies on in vivo kinetics and
clinical response of each product.
Patient characteristics often affect the pharmacokinetics and
clinical response with cytotoxic chemotherapies used to treat
pediatric and young adult patients with B-ALL, most likely
because some of these attributes are associated with chemotherapy metabolism and resistance (14–16). This study found that
tisagenlecleucel in vivo activity is not related to patient-speciﬁc
factors, a ﬁnding that demonstrates that tisagenlecleucel has
the potential to expand in vivo irrespective of prior therapies
or prior hematopoietic stem cell transplantation in patients
ages  25 years. Although this ﬁnding is speciﬁc to B-ALL, as
tisagenlecleucel therapy expands into other indications, age
ranges, or becomes an earlier line of treatment it will be important
to conﬁrm in vivo expansion is not affected by patient-speciﬁc
factors that may ultimately affect efﬁcacy. Furthermore, as more
patients with B-ALL and non-Hodgkin lymphoma are treated
with tisagenlecleucel, it will be important to look for insights
into the characteristics of nonresponders.
The antibody-binding domain of tisagenlecleucel contains a
murine scFv region responsible for recognizing CD19 on the
surface of B cells; therefore, it poses a potential risk for eliciting
an immunogenic response. The guidelines for immunogenicity
assessment for therapeutic protein products (17) do not speciﬁcally outline the immunogenicity requirements for cell
and gene therapies; however, similar assessments for characterizing the impact of preexisting and treatment-induced
immunogenicity on clinical efﬁcacy, safety, and cellular kinetics
were performed for tisagenlecleucel. Characterizing immunogenicity is an important element for CAR-T therapies, speciﬁcally those that are composed of murine components. An
important ﬁnding of this study was that preexisting and treatment-induced immunogenicity did not affect the expansion,
persistence, safety, or efﬁcacy of tisagenlecleucel. As the majority of patients included in this analysis were immune suppressed, the characterization of the impact of immunogenicity
on efﬁcacy and long-term safety in immune-competent patients
post-CAR-T will be an important area for further investigation.
Traditional dose escalation studies were not performed for
tisagenlecleucel. Tisagenlecleucel is a living drug and therefore,
once infused, the cells expand beyond the initial infused dose.
Importantly, no relationship between the doses administered in
these studies and in vivo expansion was observed (Supplementary
Fig. S4). The original protocol speciﬁed a dose range of 1.0 to
5.0  106 CAR-positive viable T cells/kg for patients  50 kg and
1.0 to 2.5  108 CAR-positive viable T cells for patients > 50 kg.
The manufacturing speciﬁcations for tisagenlecleucel always targeted the high end of the dose range and treatment sites infused
the highest achievable dose for each individual patient. However,
during the course of the clinical trial, due to patient-speciﬁc
characteristics, doses within the original protocol-speciﬁed dose
range were not always able to be manufactured. For these cases,
the FDA was consulted to allow infusion of tisagenlecleucel at
doses outside the protocol-speciﬁed dose range. Each request
was approved by the FDA and ultimately the original protocolspeciﬁed dose range was broadened to reﬂect the positive beneﬁt–
risk seen at the lower doses. The administration of tisagenlecleucel
at lower doses has been shown to result in CRs in patients
presented in this pooled analysis, thus supporting the approved
dose range for tisagenlecleucel (18). Future studies should evaluate dosing in adult ALL patients beyond the age of 25 years.
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Tisagenlecleucel offers pediatric and young adult patients
with r/r B-ALL a new treatment option. These analyses show
that cellular kinetics and clinical pharmacology aspects of
tisagenlecleucel support the recommended dose range, safety,
and efﬁcacy proﬁle in pediatric and young adult patients with
r/r B-ALL. Similar analyses are being performed to characterize
the dose and its safety and efﬁcacy in each indication of
tisagenlecleucel (19, 20).
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